Best Peptides for Gut Healing — Evidence Review
"Gut healing" is one of the most marketed peptide use cases. The actual evidence — narrowed to specific GI mechanisms and animal-model or early-human data — is more focused than the marketing implies.
"Gut healing" is one of the most marketed peptide use cases. The actual evidence — narrowed to specific GI mechanisms and animal-model or early-human data — is more focused than the marketing implies.
Peptides with the strongest evidence
BPC-157
Body Protection Compound was originally isolated from gastric juice. The gut-specific animal-model evidence is the largest in the peptide literature:
- Healing of cysteamine-induced and NSAID-induced gastric ulcers
- Attenuation of NSAID-enteropathy in small intestine
- Improved outcomes in colitis and IBD models
- Restored tight-junction integrity in barrier-dysfunction models
Zero completed human trials. Oral BPC-157 has more pharmacokinetic plausibility for gut-specific effects than injectable (gastric stability is preserved due to proline content).
KPV (Lysine-Proline-Valine)
α-MSH fragment with anti-inflammatory action. Multiple preclinical studies in colitis and IBD models show reduced disease severity and lower pro-inflammatory cytokine production. Phase 1/2 IBD trials emerging.
Larazotide
Zonulin antagonist targeting intestinal tight-junction regulation. Studied in celiac disease and non-celiac gluten sensitivity. Phase 3 CeDLara trial did not meet primary endpoint, raising questions about clinical efficacy in celiac specifically. Mechanism remains relevant in autoimmune-spectrum gut conditions.
Supporting cast
LL-37
Antimicrobial peptide with roles in gut immune defense and barrier function. Therapeutic applications still being characterized. Context-dependent.
What the evidence does not support
- Claims that BPC-157 "heals leaky gut" in humans (no controlled human data exists for this specific outcome)
- "Gut healing protocols" combining 4–5 peptides without published evidence
- Use as a substitute for evaluation of GI symptoms — IBD, celiac disease, microbial overgrowth, malabsorption all have specific diagnostic pathways
- Use during active GI cancer (pro-angiogenic concern with BPC-157)
Practical considerations
GI symptoms warrant proper gastroenterology evaluation. Peptide therapy is at best adjunctive to a clear diagnosis.
For functional GI complaints (IBS, functional dyspepsia) where evaluation is unrevealing, the first-line interventions remain dietary modification (low-FODMAP for IBS), stress management, and conventional pharmacotherapy where appropriate.
For inflammatory bowel disease in active flare, biologic therapy and conventional immunosuppression remain first-line. Peptide adjunct use should be coordinated with GI specialist team.
Where to source
- BPC-157 vendor rankings — 12 ranked vendors; vendor variability is meaningful
KPV and larazotide vendor data is sparser due to lower independent testing volume.
What we don't know
- Clinical efficacy of BPC-157 in any human gut condition
- Whether oral or injectable administration produces better gut-specific outcomes in humans
- Long-term effects on gut microbiome
- Whether peptide therapy meaningfully alters disease course in IBD versus controlling existing inflammation transiently
Methodology
Read the full methodology.
This page is educational. Gut symptoms warrant proper gastroenterology evaluation. Peptide therapy is not first-line for any recognized GI condition.